RhumbLine Advisers
PRLD icon

RhumbLine Advisers’s Prelude Therapeutics PRLD Stock Holding History

RhumbLine Advisers’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$118K Buy
+22,074
New +$96.1K ﹤0.01% 3472
2025
Q2 		– Sell
-15,499
Closed -$11.9K – 4231
2025
Q1 		$11.9K Sell
15,499
-151,331
-91% -$141K ﹤0.01% 3807
2024
Q4 		$213K Buy
166,830
+154,826
+1,290% +$205K ﹤0.01% 3165
2024
Q3 		$24.8K Sell
12,004
-9,561
-44% -$44.3K ﹤0.01% 3794
2024
Q2 		$82.2K Buy
21,565
+399
+2% +$1.62K ﹤0.01% 3567
2024
Q1 		$100K Buy
21,166
+763
+4% +$2.97K ﹤0.01% 3447
2023
Q4 		$87.1K Sell
20,403
-13,412
-40% -$40.8K ﹤0.01% 3494
2023
Q3 		$104K Buy
33,815
+3,996
+13% +$15K ﹤0.01% 3447
2023
Q2 		$134K Buy
+29,819
New +$178K ﹤0.01% 3415
2022
Q2 		– Sell
-10,050
Closed -$69K – 3205
2022
Q1 		$69K Buy
+10,050
New +$91.9K ﹤0.01% 2948
2021
Q4 		– Sell
-9,275
Closed -$290K – 3020
2021
Q3 		$290K Buy
9,275
+500
+6% +$16.2K ﹤0.01% 2779
2021
Q2 		$251K Sell
8,775
-886
-9% -$31.5K ﹤0.01% 2858
2021
Q1 		$419K Buy
9,661
+115
+1% +$7.63K ﹤0.01% 2569
2020
Q4 		$683K Buy
+9,546
New +$475K ﹤0.01% 2311

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

RhumbLine Advisers's PRLD Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Prelude Therapeutics (PRLD) in Q2 2026: 22,074 shares worth $118K. The stake represents ﹤0.01% of the portfolio and ranks #3472 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in PRLD as recently as Q1 2025.

RhumbLine Advisers first reported a position in PRLD in Q4 2020 and has held it in 14 quarters since. The position peaked at $683K in Q4 2020. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • RhumbLine Advisers held 22,074 shares of Prelude Therapeutics worth $118K as of Q2 2026.
  • Prelude Therapeutics was a new RhumbLine Advisers position in Q2 2026.
  • Prelude Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3472 holding.
  • RhumbLine Advisers first reported a position in Prelude Therapeutics in Q4 2020 and has held it in 14 quarters since.
  • RhumbLine Advisers's Prelude Therapeutics position peaked at $683K in Q4 2020.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.